{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:51:57Z","timestamp":1791899517049,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006967","name":"Center for AIDS Research, Duke University","doi-asserted-by":"publisher","award":["5P30 AI064518"],"award-info":[{"award-number":["5P30 AI064518"]}],"id":[{"id":"10.13039\/100006967","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long Acting Injectable (LAI) therapy to treat HIV is an alternative to daily oral medications. The success of early roll-out of LAI to eligible patients requires a better understanding of patients\u2019 awareness and interest in this novel therapy. We administered an electronic survey to patients attending an urban HIV clinic in the US South. Eligible participants were 18\u2009+\u2009years old with a most recent HIV-1 viral load\u2009&lt;\u2009200 copies\/ml, without any evidence of genotypic resistance to LAI components or chronic hepatitis B. Survey recipients were asked about current treatment, engagement in care, and knowledge of LAI. Between January-April 2023, 480 patients were screened; 319 were eligible, and 155 (49%) completed the survey. The majority (119, 77%) were aware of, and 87 (56%) were interested in LAI. In regression analysis, only age was associated with interest in LAI (OR 0.95, 95% CI 0.92,0.99). Among proposed benefits of injectables, ease of travel without pills, lack of daily pill-taking, and fewer medication interactions were most appealing. Among proposed concerns with injectables, higher cost and insurance coverage of the new medicine were most worrisome. A large majority of people with HIV (PWH) are aware of the newest treatment available, and just over half of our sample expressed interest in LAI. Older age was associated with lower interest in LAI. LAI is appealing for its convenience, privacy, and avoidance of drug interactions, while the increased costs associated with LAI need to be addressed.<\/jats:p>","DOI":"10.1007\/s10461-024-04423-x","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T05:25:09Z","timestamp":1719897909000},"page":"3315-3325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Jacob A.","family":"Stout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Allamong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliburn","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Muiruri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sauceda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2942-5398","authenticated-orcid":false,"given":"Mehri S.","family":"McKellar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"issue":"10267","key":"4423_CR1","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"19","author":"ET Overton","year":"2021","unstructured":"Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet Dec. 2021;19(10267):1994\u20132005.","journal-title":"Lancet Dec"},{"issue":"11","key":"4423_CR2","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","volume":"8","author":"H Jaeger","year":"2021","unstructured":"Jaeger H, Overton ET, Richmond G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV Nov. 2021;8(11):e679\u201389.","journal-title":"Lancet HIV Nov"},{"key":"4423_CR3","unstructured":"CAB\u2009+\u2009RPV Prescribing Info. In. Healthcare V, editor: Food and Drug Administration; 2022."},{"issue":"11","key":"4423_CR4","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2217\/nnm.12.214","volume":"8","author":"J Williams","year":"2013","unstructured":"Williams J, Sayles HR, Meza JL, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomed (Lond) Nov. 2013;8(11):1807\u201313.","journal-title":"Nanomed (Lond) Nov"},{"issue":"7","key":"4423_CR5","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s10508-017-1049-7","volume":"47","author":"KB Biello","year":"2018","unstructured":"Biello KB, Hosek S, Drucker MT, et al. Preferences for Injectable PrEP among Young U.S. Cisgender men and Transgender women and men who have sex with men. Arch Sex Behav Oct. 2018;47(7):2101\u20137.","journal-title":"Arch Sex Behav Oct"},{"issue":"4","key":"4423_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1089\/aid.2019.0175","volume":"36","author":"K Dub\u00e9","year":"2020","unstructured":"Dub\u00e9 K, Eskaf S, Evans D, et al. The dose response: perceptions of people living with HIV in the United States on Alternatives to oral daily antiretroviral therapy. AIDS Res Hum Retroviruses Apr. 2020;36(4):324\u201348.","journal-title":"AIDS Res Hum Retroviruses Apr"},{"issue":"3","key":"4423_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/apc.2018.0198","volume":"33","author":"JM Simoni","year":"2019","unstructured":"Simoni JM, Beima-Sofie K, Mohamed ZH, et al. Long-acting Injectable Antiretroviral Treatment Acceptability and preferences: a qualitative study among US Providers, adults living with HIV, and parents of Youth living with HIV. AIDS Patient Care STDS Mar. 2019;33(3):104\u201311.","journal-title":"AIDS Patient Care STDS Mar"},{"key":"4423_CR8","doi-asserted-by":"crossref","first-page":"232595822098126","DOI":"10.1177\/2325958220981265","volume":"19","author":"DE Koren","year":"2020","unstructured":"Koren DE, Fedkiv V, Zhao H, et al. Perceptions of long-acting Injectable Antiretroviral Treatment regimens in a United States Urban Academic Medical Center. J Int Assoc Provid AIDS Care Jan-Dec. 2020;19:2325958220981265.","journal-title":"J Int Assoc Provid AIDS Care Jan-Dec"},{"issue":"sup2","key":"4423_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/09540121.2020.1742869","volume":"32","author":"S Carillon","year":"2020","unstructured":"Carillon S, Gallardo L, Linard F, et al. Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users\u2019 ambivalences. AIDS Care May. 2020;32(sup2):155\u201361.","journal-title":"AIDS Care May"},{"key":"4423_CR10","doi-asserted-by":"crossref","first-page":"232595822110005","DOI":"10.1177\/23259582211000517","volume":"20","author":"JM Simoni","year":"2021","unstructured":"Simoni JM, Beima-Sofie K, Wanje G, et al. Lighten this Burden of ours: acceptability and preferences regarding injectable antiretroviral treatment among adults and Youth Living with HIV in Coastal Kenya. J Int Assoc Provid AIDS Care Jan-Dec. 2021;20:23259582211000517.","journal-title":"J Int Assoc Provid AIDS Care Jan-Dec"},{"issue":"1","key":"4423_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/apc.2020.0164","volume":"35","author":"MM Philbin","year":"2021","unstructured":"Philbin MM, Parish C, Bergen S, et al. A qualitative exploration of women\u2019s interest in Long-Acting Injectable Antiretroviral Therapy Across Six cities in the women\u2019s interagency HIV Study: intersections with current and past injectable medication and substance use. AIDS Patient Care STDS Jan. 2021;35(1):23\u201330.","journal-title":"AIDS Patient Care STDS Jan"},{"issue":"2","key":"4423_CR12","doi-asserted-by":"publisher","first-page":"e0262926","DOI":"10.1371\/journal.pone.0262926","volume":"17","author":"O Jolayemi","year":"2022","unstructured":"Jolayemi O, Bogart LM, Storholm ED, et al. Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: a qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. PLoS ONE. 2022;17(2):e0262926.","journal-title":"PLoS ONE"},{"issue":"2","key":"4423_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11136-022-03290-0","volume":"32","author":"LS Matza","year":"2023","unstructured":"Matza LS, Howell TA, Chounta V, van de Velde N. Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV. Qual Life Res Feb. 2023;32(2):531\u201341.","journal-title":"Qual Life Res Feb"},{"key":"4423_CR14","doi-asserted-by":"crossref","first-page":"232595822110090","DOI":"10.1177\/23259582211009011","volume":"20","author":"KK Scarsi","year":"2021","unstructured":"Scarsi KK, Swindells S. The Promise of Improved Adherence with Long-acting antiretroviral therapy: what are the data? J Int Assoc Provid AIDS Care Jan-Dec. 2021;20:23259582211009011.","journal-title":"J Int Assoc Provid AIDS Care Jan-Dec"},{"issue":"10101","key":"4423_CR15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"23","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet Sep. 2017;23(10101):1499\u2013510.","journal-title":"Lancet Sep"},{"issue":"12","key":"4423_CR16","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1007\/s10461-020-02918-x","volume":"24","author":"A Mantsios","year":"2020","unstructured":"Mantsios A, Murray M, Karver TS, et al. Efficacy and freedom: patient experiences with the transition from daily oral to long-acting Injectable Antiretroviral Therapy to treat HIV in the context of phase 3 trials. AIDS Behav Dec. 2020;24(12):3473\u201381.","journal-title":"AIDS Behav Dec"},{"issue":"12","key":"4423_CR17","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","volume":"24","author":"M Murray","year":"2020","unstructured":"Murray M, Antela A, Mills A, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of Cabotegravir and Rilpivirine over 48 weeks. AIDS Behav Dec. 2020;24(12):3533\u201344.","journal-title":"AIDS Behav Dec"},{"issue":"6","key":"4423_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","volume":"14","author":"V Chounta","year":"2021","unstructured":"Chounta V, Overton ET, Mills A, et al. Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and Rilpivirine Administered Every 4 or 8 weeks (ATLAS-2\u00a0M). Patient Nov. 2021;14(6):849\u201362.","journal-title":"Patient Nov"},{"key":"4423_CR19","volume-title":"Diagnoses of HIV infection in the United States and dependent areas, 2021","author":"CDC","year":"2023","unstructured":"CDC. Diagnoses of HIV infection in the United States and dependent areas, 2021. CDC Website: CDC; 2023."},{"issue":"2","key":"4423_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/QAI.0000000000002000","volume":"1","author":"MO Johnson","year":"2019","unstructured":"Johnson MO, Neilands TB, Koester KA, et al. Detecting disengagement from HIV Care before it is too late: development and preliminary validation of a Novel Index of Engagement in HIV Care. J Acquir Immune Defic Syndr Jun. 2019;1(2):145\u201352.","journal-title":"J Acquir Immune Defic Syndr Jun"},{"issue":"7","key":"4423_CR21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1037\/hea0000865","volume":"39","author":"JA Sauceda","year":"2020","unstructured":"Sauceda JA, Lisha NE, Dilworth SE, et al. Measuring engagement in HIV care: measurement invariance in three racial\/ethnic patient groups. Health Psychol Jul. 2020;39(7):622\u201331.","journal-title":"Health Psychol Jul"},{"issue":"7","key":"4423_CR22","doi-asserted-by":"publisher","first-page":"e2175","DOI":"10.1093\/cid\/ciaa1892","volume":"5","author":"KA Christopoulos","year":"2021","unstructured":"Christopoulos KA, Neilands TB, Koester KA, et al. The human immunodeficiency virus (HIV) Index: using a patient-reported outcome on Engagement in HIV Care to explain suboptimal Retention in Care and Virologic Control. Clin Infect Dis Oct. 2021;5(7):e2175\u201383.","journal-title":"Clin Infect Dis Oct"},{"key":"4423_CR23","doi-asserted-by":"crossref","unstructured":"Sauceda JA, Lisha NE, Ludwig-Barron N et al. The brief HIV Index: a rapid 3-item scale to measure engagement in HIV care. Clin Infect Dis Apr 5 2023.","DOI":"10.1093\/cid\/ciad200"},{"issue":"6","key":"4423_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/09540121.2020.1764906","volume":"33","author":"D Dandachi","year":"2021","unstructured":"Dandachi D, Dang BN, Lucari B, Swindells S, Giordano TP. Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection. AIDS Care Jun. 2021;33(6):801\u20139.","journal-title":"AIDS Care Jun"},{"issue":"8","key":"4423_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/sextrans-2020-054648","volume":"97","author":"B Akinwunmi","year":"2021","unstructured":"Akinwunmi B, Buchenberger D, Scherzer J, et al. Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries. Sex Transm Infect Dec. 2021;97(8):566\u201373.","journal-title":"Sex Transm Infect Dec"},{"issue":"4","key":"4423_CR26","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10461-022-03865-5","volume":"27","author":"F Yu","year":"2023","unstructured":"Yu F, Hsiao YH, Park S, et al. The influence of anticipated HIV Stigma on Health-related behaviors, self-rated Health, and treatment preferences among people living with HIV in East Asia. AIDS Behav Apr. 2023;27(4):1287\u2013303.","journal-title":"AIDS Behav Apr"},{"issue":"7","key":"4423_CR27","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1007\/s10461-022-03964-3","volume":"27","author":"D Feihel","year":"2023","unstructured":"Feihel D, Spier D, Stevens T, Stefanov DG, Ahmadi L. Acceptance Rate and reasons for rejection of long acting Injectable antiretrovirals. AIDS Behav Jul. 2023;27(7):2370\u20135.","journal-title":"AIDS Behav Jul"},{"key":"4423_CR28","doi-asserted-by":"crossref","unstructured":"Barthold D, Saldarriaga EM, Brah AT et al. Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV. Aids Jun 7. 2023.","DOI":"10.1097\/QAD.0000000000003620"},{"issue":"7","key":"4423_CR29","doi-asserted-by":"publisher","first-page":"ofac293","DOI":"10.1093\/ofid\/ofac293","volume":"9","author":"KA Christopoulos","year":"2022","unstructured":"Christopoulos KA, Colasanti J, Johnson MO, et al. Are patients and their providers talking about long-acting Injectable Antiretroviral Therapy? Penetration into clinical encounters at three U.S. Care sites. Open Forum Infect Dis Jul. 2022;9(7):ofac293.","journal-title":"Open Forum Infect Dis Jul"},{"issue":"13","key":"4423_CR30","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1080\/14656566.2022.2126310","volume":"23","author":"H Qazzaz","year":"2022","unstructured":"Qazzaz H, Parganas C, Cory TJ. An evaluation of long-acting cabotegravir\u2009+\u2009rilpivirine for the treatment of virologically suppressed adults living with HIV. Expert Opin Pharmacother Sep. 2022;23(13):1485\u201395.","journal-title":"Expert Opin Pharmacother Sep"},{"key":"4423_CR31","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2147\/PPA.S405288","volume":"17","author":"S Fifer","year":"2023","unstructured":"Fifer S, Kularatne T, Tan M, Drummond F, Rule J. Understanding treatment preferences among people living with HIV in Australia: a Discrete Choice Experiment. Patient Prefer Adherence. 2023;17:1825\u201343.","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"4423_CR32","doi-asserted-by":"publisher","first-page":"ofac455","DOI":"10.1093\/ofid\/ofac455","volume":"9","author":"LF Collins","year":"2022","unstructured":"Collins LF, Corbin-Johnson D, Asrat M, et al. Early experience implementing long-acting Injectable Cabotegravir\/Rilpivirine for Human Immunodeficiency Virus-1 treatment at a Ryan White-Funded Clinic in the US South. Open Forum Infect Dis Sep. 2022;9(9):ofac455.","journal-title":"Open Forum Infect Dis Sep"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04423-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-024-04423-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04423-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T05:05:26Z","timestamp":1727327126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-024-04423-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["4423"],"URL":"https:\/\/doi.org\/10.1007\/s10461-024-04423-x","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"18 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAS, MA, FH, CC, KL, JS have no disclosures to report. MSM receives institutional funding from Gilead Sciences. CM is supported by a grant from the NHLBI, an institute of the NIH (K01HL159052).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All patients provided electronic consent to participation at the initiation of the survey. This study was approved by the Duke University Health System\u2019s Institutional Review Board (Pro00111870).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent"}}]}}